Issue 89 of the Cuadernos de Derecho Farmacéutico (Pharmaceutical Law Review) journal

Don’t miss out on this issue of Cuadernos de Derecho Farmacéutico, which examines the following:

The current regulatory framework for advertising medical products, the changes brought about by the new Royal Decree on the advertising of medical products and the impact that the new Royal Decree will have on competition in the industry, with a particular emphasis on the opinion issued by the Spanish National Markets and Competition Commission (CNMC) in its report of April 2024.
The constitutional significance of the obstacles and difficulties in accessing medicinal products not included in the Spanish National Health System’s pharmaceutical funding. Identifying a lack of legal certainty, deficient dissemination of the applicable rules, territorial inequality and lack of equity. Denying access to a medicinal product may even be contrary to the right to life and health protection. Some recent cases are discussed.
The challenges and opportunities facing the regulation of artificial intelligence, and the current status of its legal and regulatory framework, with a special focus on the pharmaceutical sector. Artificial intelligence has revolutionised the pharmaceutical sector, offering unprecedented opportunities to enhance research and development for the benefit of society. However, the use of this technology also poses significant regulatory challenges that require a careful and balanced approach to ensure safety, efficacy and ethics in its application.

This post is also available in: Spanish

Address